ACW pivotal Alzheimers trial database lock - results mid-Nov
Filed with ASX · · 3 pages · English
Summary by 6ix AI
Actinogen Medical Limited has announced the achievement of a database lock for its XanaMIA pivotal Alzheimer’s disease trial, confirming that topline results are now expected in mid-November. The database lock indicates that the trial data is finalized and will undergo statistical analysis to produce final results. Dr. Steven Gourlay, CEO, expressed optimism about the potential of Xanamem as a treatment option for Alzheimer’s patients.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Actinogen Medical Limited on 6ix
Story so far
Earlier from Actinogen Medical
- ACW September 2026 quarterly activity report & Appendix 4C
- Notification of buy-back - ACW
- AGM date and closing date for director nominations
- Application for quotation of securities - ACW
- Actinogen XanaMIA pivotal Alzheimer’s disease trial completes final patient visit, with topline results on track for November
Later from Actinogen Medical
- Actinogen receives $10.8m R&D tax incentive rebate from ATO
- Letter to Shareholders, Notice of AGM & Proxy Form
Follow Actinogen Medical into a list and get an email when it puts out news.
Follow Actinogen Medical